# Clinical Trial Landscape: 13_nsclc_alk_cns_disease

*Generated: 2026-01-05 18:33:41*

## Summary

- **Total Trials**: 90
- **Flagged for Review**: 0
- **Search Terms Used**: 10

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 21 | ████ 23.3% |
| Phase 1/Phase 2 | 17 | ███ 18.9% |
| Phase 1 | 15 | ███ 16.7% |
| Unknown | 14 | ███ 15.6% |
| Not Applicable | 12 | ██ 13.3% |
| Phase 3 | 7 | █ 7.8% |
| Phase 2/Phase 3 | 4 |  4.4% |

## Status Distribution

- **Recruiting**: 84 (93.3%)
- **Not yet recruiting**: 5 (5.6%)
- **Enrolling by invitation**: 1 (1.1%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 4 |
| M.D. Anderson Cancer Center | 4 |
| Vanderbilt-Ingram Cancer Center | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Mayo Clinic | 3 |
| Bristol-Myers Squibb | 3 |
| SWOG Cancer Research Network | 2 |
| VA Office of Research and Development | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Pfizer | 2 |
| National Institute of Allergy and Infectious Disea | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Turning Point Therapeutics, Inc. | 1 |
| University of Missouri-Columbia | 1 |
| Syntrix Biosystems, Inc. | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 13 |
| Carboplatin | 12 |
| Pemetrexed | 11 |
| Biospecimen Collection | 11 |
| Computed Tomography | 8 |
| Paclitaxel | 7 |
| Survey Administration | 6 |
| Cisplatin | 6 |
| Etoposide | 4 |
| Positron Emission Tomography | 4 |
| Gemcitabine | 4 |
| Magnetic Resonance Imaging | 3 |
| Nivolumab | 3 |
| Placebo | 3 |
| Docetaxel | 3 |
| Electronic Health Record Review | 3 |
| Cyclophosphamide | 2 |
| Atezolizumab | 2 |
| Durvalumab | 2 |
| Monalizumab | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 90 |
| Spain | 22 |
| Canada | 17 |
| South Korea | 17 |
| Australia | 16 |
| France | 16 |
| Italy | 16 |
| United Kingdom | 14 |
| Belgium | 13 |
| Germany | 11 |
| Japan | 11 |
| Poland | 11 |
| Taiwan | 11 |
| Turkey (Türkiye) | 10 |
| China | 9 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| ALK rearrangement | manual | 1.0 |
| ALKrearrangement | manual | 0.9 |
| ALK-rearrangement | manual | 0.9 |
| NSCLC | manual | 1.0 |
| ALK rearrangement NSCLC | manual | 1.0 |
| ALK rearrangement non-small cell lung cancer | llm | 0.9 |
| NSCLC ALK rearrangement | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung cancer | llm | 0.8 |
| EML4-ALK variant 1 | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07275216](https://clinicaltrials.gov/study/NCT07275216) | Phase 2 | Not yet recruiting | City of Hope Medical... | Phase 2 Study of Pembrolizumab With... |
| [NCT07176000](https://clinicaltrials.gov/study/NCT07176000) | Not Applicable | Not yet recruiting | Fred Hutchinson Canc... | Strengthening Awareness and Communi... |
| [NCT06538636](https://clinicaltrials.gov/study/NCT06538636) | Not Applicable | Not yet recruiting | VA Office of Researc... | Prediction Augmented Screening Init... |
| [NCT07216404](https://clinicaltrials.gov/study/NCT07216404) | Phase 2 | Not yet recruiting | Alan Davis | Exploring the Safety, Acceptability... |
| [NCT07063745](https://clinicaltrials.gov/study/NCT07063745) | Phase 2/Phase 3 | Recruiting | Bristol-Myers Squibb | A Randomized Phase 2/3 Study of BMS... |
| [NCT06945484](https://clinicaltrials.gov/study/NCT06945484) | Not Applicable | Not yet recruiting | University of Utah | PILOT for The Precision Exercise Re... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07217171](https://clinicaltrials.gov/study/NCT07217171) | Phase 1 | Recruiting | EvolveImmune United,... | A Phase 1 Dose-Escalation and Expan... |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Phase 2 | Recruiting | Diwakar Davar | Patient Preference for Subcutaneous... |
| [NCT07220096](https://clinicaltrials.gov/study/NCT07220096) | N/A | Recruiting | M.D. Anderson Cancer... | Registry Trial and Needs Assessment... |
| [NCT07140016](https://clinicaltrials.gov/study/NCT07140016) | Phase 1 | Recruiting | Astellas Pharma Glob... | A Phase 1b Study of Gilteritinib in... |
| [NCT07090499](https://clinicaltrials.gov/study/NCT07090499) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-label Study to Inves... |
| [NCT07058064](https://clinicaltrials.gov/study/NCT07058064) | Not Applicable | Recruiting | Mayo Clinic | WATCH (Wearable Artificial inTellig... |
| [NCT07013474](https://clinicaltrials.gov/study/NCT07013474) | Phase 3 | Recruiting | Pfizer | AN INTERVENTIONAL EFFICACY AND SAFE... |
| [NCT06145763](https://clinicaltrials.gov/study/NCT06145763) | Not Applicable | Recruiting | Fred Hutchinson Canc... | Digital Smoking Cessation Intervent... |
| [NCT06995898](https://clinicaltrials.gov/study/NCT06995898) | Not Applicable | Recruiting | National Cancer Inst... | The Vanguard Study: Testing a New W... |
| [NCT06763536](https://clinicaltrials.gov/study/NCT06763536) | Not Applicable | Recruiting | Ohio State Universit... | Testing Oral Nicotine Pouches to Re... |
| [NCT06907615](https://clinicaltrials.gov/study/NCT06907615) | Phase 2 | Recruiting | Shanghai Henlius Bio... | An Open-label, Multi-center, Global... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Phase 2 | Recruiting | Mayo Clinic | Phase 2 Study of Golcadomide With R... |
| [NCT07008664](https://clinicaltrials.gov/study/NCT07008664) | N/A | Recruiting | University of Maryla... | Signature Development and Validatio... |
| [NCT06788912](https://clinicaltrials.gov/study/NCT06788912) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01E: A Phase ... |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06706076](https://clinicaltrials.gov/study/NCT06706076) | Phase 1/Phase 2 | Recruiting | BlossomHill Therapeu... | A Phase 1/2 Open-Label, Multicenter... |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | Phase 2/Phase 3 | Recruiting | BioNTech SE | A Phase II/III, Multisite, Randomiz... |
| [NCT06667076](https://clinicaltrials.gov/study/NCT06667076) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2b, Open-Label, Two-cohort ... |
| [NCT06717334](https://clinicaltrials.gov/study/NCT06717334) | N/A | Recruiting | Memorial Sloan Kette... | Enrichment of Lung Cancer Screening... |
| [NCT06660407](https://clinicaltrials.gov/study/NCT06660407) | Phase 2 | Recruiting | Mayo Clinic | Grid Radiotherapy for Advanced Non-... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Phase 1/Phase 2 | Recruiting | Daiichi Sankyo | A Multicenter, Randomized, Open-Lab... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06388564](https://clinicaltrials.gov/study/NCT06388564) | Phase 2 | Recruiting | Incyte Corporation | A Phase 2, Open-Label, Randomized, ... |
| [NCT06593106](https://clinicaltrials.gov/study/NCT06593106) | Not Applicable | Recruiting | Vanderbilt-Ingram Ca... | The CRYSTAL Study: Cryodevitalizati... |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Phase 3 | Recruiting | Bayer | A Phase 3 Open-label, Randomized, A... |
| [NCT06162572](https://clinicaltrials.gov/study/NCT06162572) | Phase 1/Phase 2 | Recruiting | Servier Bio-Innovati... | A Phase 1b/2, Multicenter, Open-lab... |
| [NCT06404086](https://clinicaltrials.gov/study/NCT06404086) | Phase 2 | Recruiting | Duke University | RECOVER-SLEEP: A Platform Protocol ... |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Not Applicable | Recruiting | University of Pittsb... | Cancer Nutrition Study: CaNS - A Pi... |
| [NCT06582745](https://clinicaltrials.gov/study/NCT06582745) | Phase 2 | Recruiting | Cook Children's Heal... | Targeted Approach to Langerhans Cel... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06262321](https://clinicaltrials.gov/study/NCT06262321) | Phase 2 | Recruiting | University of Roches... | Phase II Trial of Thoracic Radiothe... |
| [NCT06150664](https://clinicaltrials.gov/study/NCT06150664) | Phase 1 | Recruiting | Compass Therapeutics | A Phase 1, Open-Label, Multiple-Asc... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06246110](https://clinicaltrials.gov/study/NCT06246110) | Phase 2 | Recruiting | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combi... |
| [NCT05968898](https://clinicaltrials.gov/study/NCT05968898) | Not Applicable | Recruiting | Abramson Cancer Cent... | Assessment of a Radiomics-based Com... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT06131840](https://clinicaltrials.gov/study/NCT06131840) | Phase 1 | Recruiting | Seagen, a wholly own... | An Open-label Phase 1 Study to Inve... |
| [NCT06074588](https://clinicaltrials.gov/study/NCT06074588) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Randomized, Open-label, Phase 3 S... |
| [NCT05799274](https://clinicaltrials.gov/study/NCT05799274) | Phase 1 | Recruiting | Radiopharm Theranost... | Characterizing the Radiochemical an... |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Phase 2 | Recruiting | Hackensack Meridian ... | A Multicenter Phase II Randomized T... |

*... and 40 more trials (see trials.csv for full list)*
